Marizyme, Inc.

Equities

GBSX

US5703721028

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:03:30 2024-04-18 pm EDT			5-day change	1st Jan Change
0.095 ^USD	0.00%		0.00%	-5.09%

Feb. 06	Marizyme, Inc. Announces Resignation of Julie Kampf from the Board of Directors	CI
2023	Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Marizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021

March 31, 2022 at 05:02 pm EDT

Marizyme, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was USD 0.210279 million compared to USD 0.197136 million a year ago. Net loss was USD 11 million compared to USD 5.85 million a year ago.

Basic loss per share from continuing operations was USD 0.31 compared to USD 0.22 a year ago.

Latest news about Marizyme, Inc.

Marizyme, Inc. Announces Resignation of Julie Kampf from the Board of Directors	Feb. 06	CI
Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Marizyme, Inc. Announces FDA Clearance for Product, Duragraft	23-10-06	CI
Marizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18	CI
Marizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Marizyme, Inc. announced a financing transaction	23-05-14	CI
Marizyme, Inc. Announces IP Developments for DuraGraft and its Pipeline of Products	23-05-10	CI
Marizyme, Inc. announced that it has received $0.265216 million in funding	23-05-09	CI
Marizyme, Inc. announced that it expects to receive $0.265216 million in funding	23-04-17	CI
Marizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Marizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Marizyme, Inc. Auditor Raises 'Going Concern' Doubt	23-03-23	CI
Marizyme, Inc. announced that it expects to receive $1 million in funding from Walleye Capital LLC	23-02-06	CI
Marizyme, Inc. announced that it has received $0.75 million in funding	22-12-27	CI
Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Marizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Marizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Marizyme, Inc. Appoints Michael R. Stewart to the Board, Effective June 1, 2022	22-05-12	CI
Marizyme, Inc. Appoints Nilesh Patel to Board as Director	22-04-25	CI
Marizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
Marizyme, Inc. Auditor Raises 'Going Concern' Doubt	22-03-30	CI
MMarizyme, Inc. Announces Allowance of Patent Application for Duragraft® by United States Patent and Trademark Office	22-01-05	CI
Marizyme, Inc. Appoints David Barthel as Member of Board of Directors	21-12-23	CI
Marizyme, Inc. Appoints George Kovalyov as CFO	21-12-23	CI
Marizyme, Inc. completed the acquisition of My Health Logic Inc. from Health Logic Interactive Inc. (TSXV:CHIP.H).	21-12-21	CI

Chart Marizyme, Inc.

Duration

Period

More charts

Company Profile

Marizyme, Inc. is a multi-technology life science company. The Company is engaged in the development and commercialization of medical technologies that improves patient health outcomes. Its products include DuraGraft, MATLOC 1 and Krillase. DuraGraft is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. MATLOC is a lab-on-chip digital screening and diagnostic device platform, which is being developed for quantitative chronic kidney disease (CKD) assessment. Krillase can be used in the treatment of chronic wounds and burns, and other clinical applications. Its DuraGraft is an endothelial damage inhibitor (EDI), indicated for cardiac bypass, peripheral bypass, and other vascular surgeries.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MARIZYME, INC.	-5.09%	4.43M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs